Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis.

[en] [en] BACKGROUND: Pulmonary fibrosis is an emerging complication of SARS-CoV-2 infection. In this study, we speculate that patients with COVID-19 and idiopathic pulmonary fibrosis (IPF) may share aberrant expressed microRNAs (miRNAs) associated to the progression of lung fibrosis. OBJECTIVE: To identify miRNAs presenting similar alteration in COVID-19 and IPF, and describe their impact on fibrogenesis. METHODS: A systematic review of the literature published between 2010 and January 2022 (PROSPERO, CRD42022341016) was conducted using the key words (COVID-19 OR SARS-CoV-2) AND (microRNA OR miRNA) or (idiopathic pulmonary fibrosis OR IPF) AND (microRNA OR miRNA) in Title/Abstract. RESULTS: Of the 1988 references considered, 70 original articles were appropriate for data extraction: 27 studies focused on miRNAs in COVID-19, and 43 on miRNAs in IPF. 34 miRNAs were overlapping in COVID-19 and IPF, 7 miRNAs presenting an upregulation (miR-19a-3p, miR-200c-3p, miR-21-5p, miR-145-5p, miR-199a-5p, miR-23b and miR-424) and 9 miRNAs a downregulation (miR-17-5p, miR-20a-5p, miR-92a-3p, miR-141-3p, miR-16-5p, miR-142-5p, miR-486-5p, miR-708-3p and miR-150-5p). CONCLUSION: Several studies reported elevated levels of profibrotic miRNAs in COVID-19 context. In addition, the balance of antifibrotic miRNAs responsible of the modulation of fibrotic processes is impaired in COVID-19. This evidence suggests that the deregulation of fibrotic-related miRNAs participates in the development of fibrotic lesions in the lung of post-COVID-19 patients.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Guiot, Julien ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Henket, Monique ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Remacle, Claire ; Université de Liège - ULiège > GIGA > GIGA Cancer - Molecular Angiogenesis Laboratory

Cambier, Maureen ; Université de Liège - ULiège > GIGA > GIGA Cancer - Molecular Angiogenesis Laboratory

Struman, Ingrid ; Université de Liège - ULiège > GIGA > GIGA Cancer - Molecular Angiogenesis Laboratory

Winandy, Marie-Laurence ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Moermans, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Louis, Edouard ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive

Malaise, Michel ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie

Ribbens, Clio ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie

Louis, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie

Njock, Makon-Sébastien ; Université de Liège - ULiège > GIGA > GIGA I3 - Pneumology

Language :

English

Title :

Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis.

Publication date :

15 April 2023

Journal title :

Respiratory Research

ISSN :

1465-9921

eISSN :

1465-993X

Publisher :

Springer Science and Business Media LLC, England

Volume :

Issue :

Pages :

112

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://link.springer.com/content/pdf/10.1186/s12931-023-02413-6.pdf

Funders :

CHU Liège - Centre Hospitalier Universitaire de Liège [BE]

Funding text :

Fonds d’Investissement de Recherche Scientifique du Centre Hospitalier Universitaire de Liège

Available on ORBi :

since 17 April 2023

Statistics

Number of views

70 (10 by ULiège)

Number of downloads

30 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

WHO Coronavirus (COVID-19) Dashboard. 2022. https://covid19.who.int. Accessed 25 May 2022.
Hasan SS, Capstick T, Ahmed R, Kow CS, Mazhar F, Merchant H, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020;14:1149–63.
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of Coronavirus (COVID-19). In: Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R, editors. StatPearls. Treasure Island: StatPearls publishing; 2020.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323:1574–81.
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020;2:1069–76.
George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807–15.
Fadista J, Kraven LM, Karjalainen J, Andrews SJ, Geller F, COVID-19 Host Genetics Initiative, et al. Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity. EBioMedicine. 2021;65:103277.
Rai DK, Kumar S, Sahay N. Post-COVID-19 pulmonary fibrosis: a case series and review of literature. J Family Med Prim Care. 2021;10:2028–31.
John AE, Joseph C, Jenkins G, Tatler AL. COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts. Immunol Rev. 2021;302:228–40.
Hama Amin BJ, Kakamad FH, Ahmed GS, Ahmed SF, Abdulla BA, Mohammed SH, et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Ann Med Surg (Lond). 2022;77: 103590.
Alhiyari MA, Ata F, Alghizzawi MI, Bilal AB, Abdulhadi AS, Yousaf Z. Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection. IDCases. 2021;23: e01041.
McGroder CF, Zhang D, Choudhury MA, Salvatore MM, D’Souza BM, Hoffman EA, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax. 2021;76:1242–5.
Nabahati M, Ebrahimpour S, Khaleghnejad Tabari R, Mehraeen R. Post-COVID-19 pulmonary fibrosis and its predictive factors: a prospective study. Egypt J Radiol Nucl Med. 2021;52:248.
Aul DR, Gates DJ, Draper DA, Dunleavy DA, Ruickbie DS, Meredith DH, et al. Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. Respir Med. 2021;188: 106602.
Patil SV, Gondhali G, Patil R. Post-Covid-19 lung fibrosis: study of 600 cases in tertiary care setting in India. Eur Respir J. 2021;5:58.
Darcis G, Bouquegneau A, Maes N, Thys M, Henket M, Labye F, et al. Long-term clinical follow-up of patients suffering from moderate-to-severe COVID-19 infection: a monocentric prospective observational cohort study. Int J Infect Dis. 2021;109:209–16.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.
King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–61.
Guiot J, Duysinx B, Seidel L, Henket M, Gester F, Bonhomme O, et al. Clinical experience in idiopathic pulmonary fibrosis: a retrospective study. Acta Clin Belg. 2018;73:139–43.
Behr J, Nathan SD, Wuyts WA, Bishop NM, Bouros DE, Antoniou K, et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9:85–95.
Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208:1339–50.
Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–23.
Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008;455:64–71.
Cheng HS, Njock M-S, Khyzha N, Dang LT, Fish JE. Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation. Front Genet. 2014;5:422.
Njock M-S, Fish JE. Endothelial miRNAs as cellular messengers in cardiometabolic diseases. Trends Endocrinol Metab. 2017;28:237–46.
Njock M-S, O’Grady T, Nivelles O, Lion M, Jacques S, Cambier M, et al. Endothelial extracellular vesicles promote tumour growth by tumour-associated macrophage reprogramming. J Extracell Vesicles. 2022;11: e12228.
Veitch S, Njock M-S, Chandy M, Siraj MA, Chi L, Mak H, et al. MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes. Cardiovasc Diabetol. 2022;21:31.
Njock M-S, Guiot J, Henket MA, Nivelles O, Thiry M, Dequiedt F, et al. Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis. Thorax. 2019;74:309–12.
Parzibut G, Henket M, Moermans C, Struman I, Louis E, Malaise M, et al. A blood exosomal miRNA signature in acute respiratory distress syndrome. Front Mol Biosci. 2021;8: 640042.
Barker KR, Lu Z, Kim H, Zheng Y, Chen J, Conroy AL, et al. miR-155 modifies inflammation, endothelial activation and blood-brain barrier dysfunction in cerebral malaria. Mol Med. 2017;23:24–33.
Njock M-S, Cheng HS, Dang LT, Nazari-Jahantigh M, Lau AC, Boudreau E, et al. Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs. Blood. 2015;125:3202–12.
Guiot J, Cambier M, Boeckx A, Henket M, Nivelles O, Gester F, et al. Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p. Thorax. 2020;75:870–81.
Yang C-Y, Chen Y-H, Liu P-J, Hu W-C, Lu K-C, Tsai K-W. The emerging role of miRNAs in the pathogenesis of COVID-19: protective effects of nutraceutical polyphenolic compounds against SARS-CoV-2 infection. Int J Med Sci. 2022;19:1340–56.
Marchi R, Sugita B, Centa A, Fonseca AS, Bortoletto S, Fiorentin K, et al. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review. Infect Genet Evol. 2021;91: 104832.
Matarese A, Gambardella J, Sardu C, Santulli G. miR-98 regulates TMPRSS2 Expression in human endothelial cells: key implications for COVID-19. Biomedicines. 2020;8:462.
Lu D, Chatterjee S, Xiao K, Riedel I, Wang Y, Foo R, et al. MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes. J Mol Cell Cardiol. 2020;148:46–9.
Haddad H, Al-Zyoud W. miRNA target prediction might explain the reduced transmission of SARS-CoV-2 in Jordan, Middle East. Noncoding RNA Res. 2020;5:135–43.
Ali Hosseini Rad SM, McLellan AD. Implications of sars-cov-2 mutations for genomic rna structure and host microrna targeting. Int J Mol Sci. 2020;21:1–18.
Khan MA-A-K, Sany MRU, Islam MS, Islam AB. Epigenetic regulator miRNA pattern differences among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 world-wide isolates delineated the mystery behind the epic pathogenicity and distinct clinical characteristics of pandemic COVID-19. Front Genet. 2020;11:765.
Chow JT-S, Salmena L. Prediction and analysis of SARS-CoV-2-targeting microRNA in human lung epithelium. Genes (Basel). 2020;11:1002.
Akula SM, Bolin P, Cook PP. Cellular miR-150–5p may have a crucial role to play in the biology of SARS-CoV-2 infection by regulating nsp10 gene. RNA Biol. 2022;19:1–11.
Bartoszewski R, Dabrowski M, Jakiela B, Matalon S, Harrod KS, Sanak M, et al. SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs. Am J Physiol Lung Cell Mol Physiol. 2020;319:L444–55.
Chen L, Zhong L. Genomics functional analysis and drug screening of SARS-CoV-2. Genes Dis. 2020;7:542–50.
Ali M, Abdullah F, Naveed A, Ahmed SM, Khan AA, Hasan A. Role of circulatory miRNA-21 and associated signaling pathways in the pathogenesis of pulmonary fibrosis among individuals recovered after COVID-19 infection. Human Gene. 2022;34: 201093.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.
Fayyad-Kazan M, Makki R, Skafi N, El Homsi M, Hamade A, El Majzoub R, et al. Circulating miRNAs: potential diagnostic role for coronavirus disease 2019 (COVID-19). Infect Genet Evol. 2021;94: 105020.
Kadota T, Yoshioka Y, Fujita Y, Araya J, Minagawa S, Hara H, et al. Extracellular vesicles from fibroblasts induce epithelial-cell senescence in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2020;63:623–36.
Pimenta R, Viana NI, Dos Santos GA, Candido P, Guimarães VR, Romão P, et al. MiR-200c-3p expression may be associated with worsening of the clinical course of patients with COVID-19. Mol Biol Res Commun. 2021;10:141–7.
Mitchell MI, Ben-Dov IZ, Liu C, Ye K, Chow K, Kramer Y, et al. Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release (EV-CATCHER): a customizable purification assay designed for small-RNA biomarker identification and evaluation of circulating small-EVs. J Extracell Vesicles. 2021;10: e12110.
Yang G, Yang L, Wang W, Wang J, Wang J, Xu Z. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression. Gene. 2015;562:138–44.
Yamada M, Kubo H, Ota C, Takahashi T, Tando Y, Suzuki T, et al. The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells. Respir Res. 2013;14:95.
Yang S, Banerjee S, De Freitas A, Sanders YY, Ding Q, Matalon S, et al. Participation of miR-200 in pulmonary fibrosis. Am J Pathol. 2012;180:484–93.
Saulle I, Garziano M, Fenizia C, Cappelletti G, Parisi F, Clerici M, et al. MiRNA profiling in plasma and placenta of SARS-CoV-2-infected pregnant women. Cells. 2021;10:1788.
Garg A, Seeliger B, Derda AA, Xiao K, Gietz A, Scherf K, et al. Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail. 2021;23:468–75.
Li P, Li J, Chen T, Wang H, Chu H, Chang J, et al. Expression analysis of serum microRNAs in idiopathic pulmonary fibrosis. Int J Mol Med. 2014;33:1554–62.
Li P, Zhao G-Q, Chen T-F, Chang J-X, Wang H-Q, Chen S-S, et al. Serum miR-21 and miR-155 expression in idiopathic pulmonary fibrosis. J Asthma. 2013;50:960–4.
Makiguchi T, Yamada M, Yoshioka Y, Sugiura H, Koarai A, Chiba S, et al. Serum extracellular vesicular miR-21-5p is a predictor of the prognosis in idiopathic pulmonary fibrosis. Respir Res. 2016;17:110.
Parray A, Mir FA, Doudin A, Iskandarani A, Danjuma IMM, Kuni RAT, et al. SnoRNAs and miRNAs networks underlying COVID-19 disease severity. Vaccines (Basel). 2021;9:1056.
de Gonzalo-Calvo D, Benítez ID, Pinilla L, Carratalá A, Moncusí-Moix A, Gort-Paniello C, et al. Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. Transl Res. 2021;236:147–59.
Lino Cardenas CL, Henaoui IS, Courcot E, Roderburg C, Cauffiez C, Aubert S, et al. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet. 2013;9: e1003291.
Demiray A, Sarı T, Çalışkan A, Nar R, Aksoy L, Akbubak İH. Serum microRNA signature is capable of predictive and prognostic factor for SARS-COV-2 virulence. Turk J Biochem. 2021;46:245.
Mullenbrock S, Liu F, Szak S, Hronowski X, Gao B, Juhasz P, et al. Systems analysis of transcriptomic and proteomic profiles identifies novel regulation of fibrotic programs by miRNAs in pulmonary fibrosis fibroblasts. Genes (Basel). 2018;9:E588.
Li C-X, Chen J, Lv S-K, Li J-H, Li L-L, Hu X. Whole-transcriptome RNA sequencing reveals significant differentially expressed mRNAs, miRNAs, and lncRNAs and related regulating biological pathways in the peripheral blood of COVID-19 patients. Mediators Inflamm. 2021;2021:6635925.
Berschneider B, Ellwanger DC, Baarsma HA, Thiel C, Shimbori C, White ES, et al. miR-92a regulates TGF-β1-induced WISP1 expression in pulmonary fibrosis. Int J Biochem Cell Biol. 2014;53:432–41.
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.
Chen Z, Wang X, Li L, Han M, Wang M, Li Z, et al. Construction of an autophagy interaction network based on competitive endogenous RNA reveals the key pathways and central genes of SARS-CoV-2 infection in vivo. Microb Pathog. 2021;158: 105051.
Qian W, Cai X, Qian Q, Peng W, Yu J, Zhang X, et al. lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial–mesenchymal transition by competitively binding miR-141-3p. Cell Death Dis. 2019;10:129.
Huang C, Xiao X, Yang Y, Mishra A, Liang Y, Zeng X, et al. MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation. J Biol Chem. 2017;292:16420–39.
Lacedonia D, Scioscia G, Soccio P, Conese M, Catucci L, Palladino GP, et al. Downregulation of exosomal let-7d and miR-16 in idiopathic pulmonary fibrosis. BMC Pulm Med. 2021;21:188.
Ji X, Wu B, Fan J, Han R, Luo C, Wang T, et al. The anti-fibrotic effects and mechanisms of microRNA-486-5p in pulmonary fibrosis. Sci Rep. 2015;5:14131.
Liu B, Li R, Zhang J, Meng C, Zhang J, Song X, et al. MicroRNA-708-3p as a potential therapeutic target via the ADAM17-GATA/STAT3 axis in idiopathic pulmonary fibrosis. Exp Mol Med. 2018;50: e465.
Casanova NG, Zhou T, Gonzalez-Garay ML, Lussier YA, Sweiss N, Ma S-F, et al. MicroRNA and protein-coding gene expression analysis in idiopathic pulmonary fibrosis yields novel biomarker signatures associated to survival. Transl Res. 2021;228:1–12.
Chen Y, Zhao X, Sun J, Su W, Zhang L, Li Y, et al. YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF. Cell Death Differ. 2019;26:1832–44.
Farr RJ, Rootes CL, Rowntree LC, Nguyen THO, Hensen L, Kedzierski L, et al. Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. PLoS Pathog. 2021;17: e1009759.
Xie T, Liang J, Geng Y, Liu N, Kurkciyan A, Kulur V, et al. MicroRNA-29c prevents pulmonary fibrosis by regulating epithelial cell renewal and apoptosis. Am J Respir Cell Mol Biol. 2017;57:721–32.
Tang H, Gao Y, Li Z, Miao Y, Huang Z, Liu X, et al. The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19. Clin Transl Med. 2020;10: e200.
Nho RS, Im J, Ho Y-Y, Hergert P. MicroRNA-96 inhibits FoxO3a function in IPF fibroblasts on type I collagen matrix. Am J Physiol Lung Cell Mol Physiol. 2014;307:L632-642.
Disayabutr S, Kim EK, Cha S-I, Green G, Naikawadi RP, Jones KD, et al. miR-34 miRNAs regulate cellular senescence in type II alveolar epithelial cells of patients with idiopathic pulmonary fibrosis. PLoS ONE. 2016;11: e0158367.
Donyavi T, Bokharaei-Salim F, Baghi HB, Khanaliha K, Alaei Janat-Makan M, Karimi B, et al. Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a–3p, 155–5p, and let-7b-3p in PBMC. Int Immunopharmacol. 2021;97: 107641.
Grehl C, Schultheiß C, Hoffmann K, Binder M, Altmann T, Grosse I, et al. Detection of SARS-CoV-2 derived small RNAs and changes in circulating small RNAs associated with COVID-19. Viruses. 2021;13:1593.
Keikha R, Hashemi-Shahri SM, Jebali A. The relative expression of miR-31, miR-29, miR-126, and miR-17 and their mRNA targets in the serum of COVID-19 patients with different grades during hospitalization. Eur J Med Res. 2021;26:75.
Tsitoura E, Wells AU, Karagiannis K, Lasithiotaki I, Vasarmidi E, Bibaki E, et al. MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF BAL cells. Oncotarget. 2016;7:74569–81.
Bagnato G, Roberts WN, Roman J, Gangemi S. A systematic review of overlapping microRNA patterns in systemic sclerosis and idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26: 160125.
Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008;283:14910–4.
Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207:1589–97.
Zhou J, Xu Q, Zhang Q, Wang Z, Guan S. A novel molecular mechanism of microRNA-21 inducing pulmonary fibrosis and human pulmonary fibroblast extracellular matrix through transforming growth factor β1-mediated SMADs activation. J Cell Biochem. 2018;119:7834–43.
Yang S, Cui H, Xie N, Icyuz M, Banerjee S, Antony VB, et al. MiR-145 regulates myofibroblast differentiation and lung fibrosis. FASEB J. 2013;27:2382–91.
Wu J, Huang Q, Li P, Wang Y, Zheng C, Lei X, et al. MicroRNA-145 promotes the epithelial-mesenchymal transition in peritoneal dialysis-associated fibrosis by suppressing fibroblast growth factor 10. J Biol Chem. 2019;294:15052–67.
Messner CJ, Schmidt S, Özkul D, Gaiser C, Terracciano L, Krähenbühl S, et al. Identification of miR-199a-5p, miR-214-3p and miR-99b-5p as fibrosis-specific extracellular biomarkers and promoters of HSC activation. Int J Mol Sci. 2021;22:9799.
Xiao X, Huang C, Zhao C, Gou X, Senavirathna LK, Hinsdale M, et al. Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition. Arch Biochem Biophys. 2015;566:49–57.
Huang Y, Xie Y, Abel PW, Wei P, Plowman J, Toews ML, et al. TGF-β1-induced miR-424 promotes pulmonary myofibroblast differentiation by targeting Slit2 protein expression. Biochem Pharmacol. 2020;180:114172.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435:828–33.
Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004;64:3087–95.
Dakhlallah D, Batte K, Wang Y, Cantemir-Stone CZ, Yan P, Nuovo G, et al. Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2013;187:397–405.
Xu T, Jing C, Shi Y, Miao R, Peng L, Kong S, et al. microRNA-20a enhances the epithelial-to-mesenchymal transition of colorectal cancer cells by modulating matrix metalloproteinases. Exp Ther Med. 2015;10:683–8.
Sing T, Jinnin M, Yamane K, Honda N, Makino K, Kajihara I, et al. microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology (Oxford). 2012;51:1550–6.
Liu P, Su J, Song X, Wang S. miR-92a regulates the expression levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 3 via sirtuin 1 signaling in hydrogen peroxide-induced vascular smooth muscle cells. Mol Med Rep. 2018;17:1041–8.
Huang Y, Tong J, He F, Yu X, Fan L, Hu J, et al. miR-141 regulates TGF-β1-induced epithelial-mesenchymal transition through repression of HIPK2 expression in renal tubular epithelial cells. Int J Mol Med. 2015;35:311–8.
Wang H, Zhang Y, Wu Q, Wang Y-B, Wang W. miR-16 mimics inhibit TGF-β1-induced epithelial-to-mesenchymal transition via activation of autophagy in non-small cell lung carcinoma cells. Oncol Rep. 2018;39:247–54.
Inomata M, Kamio K, Azuma A, Matsuda K, Usuki J, Morinaga A, et al. Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis. Exp Cell Res. 2021;398: 112416.
Guo C-J, Pan Q, Li D-G, Sun H, Liu B-W. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J Hepatol. 2009;50:766–78.
Pan Q, Guo C-J, Xu Q-Y, Wang J-Z, Li H, Fang C-H. miR-16 integrates signal pathways in myofibroblasts: determinant of cell fate necessary for fibrosis resolution. Cell Death Dis. 2020;11:639.
Yao Q, Xing Y, Wang Z, Liang J, Lin Q, Huang M, et al. MiR-16-5p suppresses myofibroblast activation in systemic sclerosis by inhibiting NOTCH signaling. Aging (Albany NY). 2020;13:2640–54.
Bo Y, Liu B, Yang L, Zhang L, Yan Y. Exosomes derived from miR-16-5p-overexpressing keratinocytes attenuates bleomycin-induced skin fibrosis. Biochem Biophys Res Commun. 2021;561:113–9.
Su S, Zhao Q, He C, Huang D, Liu J, Chen F, et al. miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nat Commun. 2015;6:8523.
Morizane R, Fujii S, Monkawa T, Hiratsuka K, Yamaguchi S, Homma K, et al. miR-34c attenuates epithelial-mesenchymal transition and kidney fibrosis with ureteral obstruction. Sci Rep. 2014;4:4578.
Wang Y, Ouyang M, Wang Q, Jian Z. MicroRNA-142-3p inhibits hypoxia/reoxygenation-induced apoptosis and fibrosis of cardiomyocytes by targeting high mobility group box 1. Int J Mol Med. 2016;38:1377–86.
Yang X, Dan X, Men R, Ma L, Wen M, Peng Y, et al. MiR-142-3p blocks TGF-β-induced activation of hepatic stellate cells through targeting TGFβRI. Life Sci. 2017;187:22–30.
Sato S, Chong SG, Upagupta C, Yanagihara T, Saito T, Shimbori C, et al. Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes. Thorax. 2021;76:895–906.
Cui H, Banerjee S, Xie N, Ge J, Liu R-M, Matalon S, et al. MicroRNA-27a-3p is a negative regulator of lung fibrosis by targeting myofibroblast differentiation. Am J Respir Cell Mol Biol. 2016;54:843–52.